uMRD: "the" endpoint or "an" endpoint for CLL?

Blood. 2022 Aug 25;140(8):797-798. doi: 10.1182/blood.2022016927.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Bridged Bicyclo Compounds, Heterocyclic
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell*
  • Neoplasm Recurrence, Local
  • Rituximab
  • Sulfonamides

Substances

  • Bridged Bicyclo Compounds, Heterocyclic
  • Sulfonamides
  • Rituximab
  • venetoclax